[Media Report]: "Horien" Extracellular Membrane Creates a Win-Win Situation for Medicine and Patients

Currently, the development of biomedical materials largely focuses on structural proteins or polysaccharides as regenerative medicine materials for clinical use. However, such materials have many drawbacks in clinical operation. To improve clinical use and increase ease of use, chemical cross-linking systems are often used. However, these chemical cross-linking systems make these structural proteins or polysaccharides difficult for enzymes in the body to recognize and break down, potentially causing harm to the human body with long-term use.

Horien Biotech has developed "Horien" Extracellular Membrane, which differs from current chemical processing methods for biomedical materials. It utilizes a novel patented decellularization technology, avoiding chemical purification and instead employing a green and environmentally friendly processing method to remove cells and residual antigens from fresh tissue that could cause immune problems. This preserves the medically valuable biological tissue structure and composition, resulting in the "Horien" Extracellular Membrane. This product is expected to maintain ease of use for physicians, reduce postoperative patient discomfort, and minimize wound bleeding.

Independent R&D, Seizing the Global Market

This decellularized technology can be applied to various organs using cardiac, liver, or skin substrates, offering wide applicability and cost advantages. Combined with Horien Biochemical's existing technologies, it is expected to enhance the company's competitiveness in the market and capture a share of the global $1 billion market opportunity. This year, this innovative R&D also won the "13th National Innovation Award" in the Medical Devices and Equipment category, recognized by the Biotechnology Industry Development Council.

Upon receiving the award, Horien Biochemical CEO Tsai Kuo-Tien stated, "Medical devices are products used by doctors on patients. Our company takes the most rigorous approach to considering the needs of both doctors and patients. Decellularization technology was developed in response to this need. We aim to provide doctors with easy-to-use and highly effective products, while also ensuring patient comfort and post-operative quality of life."

"Horien" Extracellular Membrane are independently developed and manufactured. The high-end consumable biomedical materials mainly used in dentistry include three main categories: bone filling materials, hemostatic materials, and regenerative membranes. With the development of "Horien" Extracellular Membrane, the company hopes to enrich its product line, facilitating combined clinical applications and increasing complementarity in dental clinical use." Horien Biochemical's Vice CEO, Ho Hsin-Yu, further elaborated on the market situation in dental clinical practice, stating, "Although the global environment is currently unfavorable, Horien Biochemical's existing marketed products—'Dental Wound Protective Materials,' 'Collagen Matrix,' and 'Collagen Bone Fillers'—remain unaffected. We will continue to expand our exports to Europe, the Middle East, Central Asia, ASEAN, Russia, and Latin America. With the addition of the award-winning "Horien" Extracellular Membrane, we will have even greater confidence in our global competitive advantage and positioning. After mass production, we also hope to leverage contract farming of pigs to drive the entire traditional pig farming industry supply chain in Taiwan into a new era of prosperity for biomedical materials."

Benefiting Patients, Breaking Through High-Price Monopoly

Horien Biochemical's Deputy CEO, He Xinyu, further explained, "For nearly four years, Horien Biochemical has consistently received government support for its decellularization development project, helping to overcome the initial funding shortages encountered in the research and development phase. This National Innovation Award further affirms the effectiveness of this decellularization technology. Currently, Horien Biochemical will first apply for its first certification from the Ministry of Health and Welfare for its biomembrane product, taking the first step towards application. In the next phase, it will gradually expand into different medical fields, providing it to physicians at reasonable prices, allowing patients suffering from diseases in Taiwan to benefit first." Given the current technological maturity, the successful development of "Horien" Extracellular Membrane is expected to break through the long-standing technological monopoly and high-price sales dominance of foreign companies. Horien Biochemical will also be the first company in Taiwan to independently develop innovative decellularized substrates as the main goal of regenerative medicine material development, making it a high-end innovative medical device product that better meets the needs of clinicians. In response to the trend of accelerated research on stem cells and human trials in developed countries, Horien Biochemical's "Horien" Extracellular Membrane product and technology are highly forward-looking and are expected to be used in various clinical fields such as stem cell research, drug-containing medical devices, and biological agents, making it the largest biomedical materials supplier in Asia.